Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.

Item
http://www.wikidata.org/entity/Q30733653
Treatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptNo improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration.Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNVTreatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements.Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.[Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice].A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration.Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-upInner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration.An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study.Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey.[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014]Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
P2860

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.

Item
http://www.wikidata.org/entity/Q30733653
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy of treatment with ran ...... PASS health services research.
@ast
Efficacy of treatment with ran ...... PASS health services research.
@en
type
label
Efficacy of treatment with ran ...... PASS health services research.
@ast
Efficacy of treatment with ran ...... PASS health services research.
@en
prefLabel
Efficacy of treatment with ran ...... PASS health services research.
@ast
Efficacy of treatment with ran ...... PASS health services research.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Efficacy of treatment with ran ...... PASS health services research.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P932